Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

04/05/2026 Eastern Time in USA The Dow Jones Industrial Average dropped by 1.13%, closing at 48941.9 points; the Nasdaq Composite dropped by 0.19%, closing at 25067.8 points; the S&P 500 Index dropped by 0.41%, closing at 7200.75 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Apollo Strategic Growth Capital Class A: Overnight gain 57.5%, Surges Amid Acquisition Agreement and Strong Quarterly Earnings Beat

Global Business Travel Group, Inc. was incorporated on October 10, 2008, initially established under Cayman Islands jurisdiction before redomiciling as a Delaware corporation on May 27, 2022. The enterprise specializes in delivering comprehensive technology-enabled differentiated solutions for business travelers, corporate clients, travel content suppliers—including airlines, hotels, ground transportation providers, and aggregators—as well as third-party travel agencies. Backed by the robust support of American Express GBT, the company is positioned to deliver superior choice, value, and experience to its clientele, establishing a distinctive value proposition in the marketplace. Operating as a central hub within the global B2B travel ecosystem, the corporation manages end-to-end logistics services for business travel operations while facilitating critical connections between enterprises, employees, travel suppliers, and other industry stakeholders.

Apollo Strategic Growth Capital Class A (GBTG) shares surged significantly following American Express Global Business Travel's announcement of a definitive acquisition agreement with Long Lake Management. The all-cash transaction is valued at $9.50 per share, representing a total enterprise value of approximately $6.3 billion and constituting a substantial premium to current trading levels. The rally was further bolstered by robust first-quarter financial performance, with earnings per share of $0.10 exceeding analyst estimates of $0.07 by approximately 42.86%. Quarterly revenues reached $840 million, surpassing expectations by 2.94% and marking a 35.27% year-over-year increase. As a core enterprise in the global B2B travel ecosystem, Global Business Travel Group's market leadership in corporate travel solutions has garnered strong investor confidence. The combination of the acquisition announcement and better-than-expected quarterly results drove the stock price up 57.5%, reflecting market optimism about the company's strategic positioning and growth prospects.

Cabaletta Bio: Overnight gain 30.3%, Surges Amid Major Equity Financing and Strategic Manufacturing Partnership with Cellares

Cabaletta Bio, Inc. is a clinical-stage biotechnology company incorporated under Delaware law in April 2017. The company's core business focuses on the development and commercialization of engineered T-cell therapies, with a strategic commitment to delivering profound, durable, and potentially curative innovative treatment solutions for patients with autoimmune diseases. Through its proprietary technology platform, the company is advancing a pipeline of cellular immunotherapy products targeting specific disease indications.

Cabaletta Bio (CABA) shares surged following multiple positive catalysts converging simultaneously. The company successfully completed a $150 million equity financing round, issuing approximately 51.7 million shares at $2.90 per share, with participation from prominent institutional investors including Bain Capital Life Sciences and Eli Lilly, demonstrating strong market confidence. The key catalyst was a 10-year commercial supply agreement with Cellares, utilizing the Cell Shuttle automated platform to provide industrial-scale manufacturing services for its lead product rese-cel. This partnership is expected to produce thousands of batches annually at industry-lowest costs, effectively addressing the scalability bottleneck in CAR-T cell therapy production. Cabaletta Bio (CABA) plans to submit a BLA application for rese-cel's myositis indication next year, with the first patient already receiving treatment using automated manufacturing, marking a significant transition from laboratory to industrial-scale production. Additionally, Cantor Fitzgerald analysts reiterated their "Overweight" rating while maintaining a $30 price target, further boosting market sentiment.

Fundrise Innovation Fund, LLC: Overnight gain 21.6%, Surges Amid Strong Innovation Sector Performance and Closed-End Fund Structure Benefits

Fundrise Innovation Fund, LLC is a limited liability company incorporated under Delaware state law and registered under the Investment Company Act of 1940, as amended, operating as a non-diversified, closed-end management investment company. The entity maintains strict compliance with applicable regulatory requirements and specializes in investment management operations.

**Fundrise Innovation Fund, LLC (VCX) Surges on Multiple Growth Catalysts** The remarkable price appreciation of Fundrise Innovation Fund, LLC (VCX) stems from a confluence of strategic and structural factors. As a closed-end management investment company registered under the Investment Company Act of 1940, VCX benefits from unique structural advantages, with its fixed share count enabling significant price appreciation when market demand intensifies. The fund's innovation-focused investment strategy has captured investor attention amid heightened market interest in cutting-edge sectors including technology innovation and artificial intelligence. As a non-diversified investment company, VCX's concentrated investment approach in specific innovation sectors delivers substantial returns when targeted industries outperform. The fund's impressive 268.0% annual return demonstrates robust market performance, attracting increased investor interest and capital inflows. Under the closed-end fund structure, this heightened demand directly translates to secondary market price appreciation, reinforcing the upward momentum in VCX shares.

The Top 10 Daily Gainers in the USA market are listed as follows: